Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(42)
DRUG(2)
laboratory biomarker analysis
6 trials
not_applicablephase_2
city-of-hope-medical-center
positron emission tomography
3 trials
not_applicablephase_2
city-of-hope-medical-center
copper Cu 64-DOTA-trastuzumab
3 trials
not_applicablephase_2
city-of-hope-medical-center
therapeutic conventional surgery
2 trials
not_applicablephase_2
city-of-hope-medical-center
Carboplatin
2 trials
phase_1_2phase_2
national-cancer-institute-nci, city-of-hope-medical-center
Computed Tomography
2 trials
not_applicablephase_2
city-of-hope-medical-center, national-cancer-institute-nci
Quality-of-Life Assessment
2 trials
not_applicablephase_1_2
city-of-hope-medical-center
trastuzumab
2 trials
not_applicablephase_2
city-of-hope-medical-center

+21 more interventions

29 unique interventions2 categories

Analytics

Trial Phases

Phase 11
Phase 24

Trial Status

Completed3
Terminated1
Other4

Role Distribution

Principal Investigator8
PI Rate100%

Activity Timeline

Clinical Trials (8)

NCT03853707Phase 1/2Completed
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
PrincipalinvestigatorStart date: 2019-03-04
NCT02778685Phase 2Active Not Recruiting
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
Metastatic Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
PrincipalinvestigatorStart date: 2016-09-30
NCT02827877Phase 2Active Not Recruiting
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
HER2 Positive Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast Cancer+1 more
PrincipalinvestigatorStart date: 2016-07-15
NCT02432950Not ApplicableCompleted
Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer
ObesityStage IA Breast CancerStage IB Breast Cancer+5 more
PrincipalinvestigatorStart date: 2016-03-22
NCT01093612Not ApplicableActive Not Recruiting
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
Breast CancerStage IV Breast Cancer
PrincipalinvestigatorStart date: 2011-03-16
NCT01149083Phase 2Completed
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Breast Carcinoma+2 more
PrincipalinvestigatorStart date: 2010-06-30
NCT01409811Not ApplicableTerminated
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
Estrogen Receptor-positive Breast CancerInvasive Ductal Breast CarcinomaProgesterone Receptor-positive Breast Cancer+4 more
Principalinvestigator
NCT02226276Not ApplicableActive Not Recruiting
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Bone MetastasesHER2-positive Breast CancerLiver Metastases+4 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Norman Wolmark, MD

NSABP Foundation Inc

Related
54 trials

Shared therapeutic areas:

Breast CancerStage IB Breast CancerStage IIB Breast Cancer+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Ali MA Ismail, lecturer

Cairo University

Related
27 trials

Shared therapeutic areas:

ObesityBreast Cancer
Similarity Score2%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Breast CancerMetastatic Breast Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Breast CancerRecurrent Breast Cancer
Similarity Score2%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Related
13 trials

Shared therapeutic areas:

Breast CancerLiver Metastases
Similarity Score2%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score1%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score1%

Jeong Min Lee, MD

Seoul National University Hospital

Related
34 trials

Shared therapeutic areas:

Liver Metastases
Similarity Score1%

Sabine Hazan, MD

ProgenaBiome

Related
41 trials

Shared therapeutic areas:

Obesity
Similarity Score1%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (8)

Showing 8 of 8 trials

NCT03853707Phase 1/2PrincipalInvestigator

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
Completed
NCT02778685Phase 2PrincipalInvestigator

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Metastatic Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
Active Not Recruiting
NCT02827877Phase 2PrincipalInvestigator

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

HER2 Positive Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast Cancer+1 more
Active Not Recruiting
NCT02432950Not ApplicablePrincipalInvestigator

Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer

ObesityStage IA Breast CancerStage IB Breast Cancer+5 more
Completed
NCT01093612Not ApplicablePrincipalInvestigator

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Breast CancerStage IV Breast Cancer
Active Not Recruiting
NCT01149083Phase 2PrincipalInvestigator

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Breast Carcinoma+2 more
Completed
NCT01409811Not ApplicablePrincipalInvestigator

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Estrogen Receptor-positive Breast CancerInvasive Ductal Breast CarcinomaProgesterone Receptor-positive Breast Cancer+4 more
Terminated
NCT02226276Not ApplicablePrincipalInvestigator

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Bone MetastasesHER2-positive Breast CancerLiver Metastases+4 more
Active Not Recruiting

All 8 trials loaded